LDS/Medical Tests/Myeloid Differentiation Primary Response 88 (MYD88) Gene Mutation Analysis

Myeloid Differentiation Primary Response 88 (MYD88) Gene Mutation Analysis

The MYD88 gene, located in the short (p) arm of chromosome 3 at position 22.2 encodes for the myeloid differentiation primary response 88 (MYD88) protein. MYD88 protein is an adapter protein involved in toll-like receptor and interleukin-1 signaling in the immune response, cytokine secretion, and inflammatory response. Patients with defects in this gene have an increased susceptibility to pyogenic bacterial infections. Mutations in the MYD88 gene have been associated with MyD88 deficiency, Waldenström macroglobulinemia and diffuse large B-cell lymphoma (DLBCL).

Germline mutations in MYD88 cause a primary immunodeficiency that effects innate immunity. Patients with MYD88 deficiency have an increased susceptibility to infections with pyogenic (pus producing) bacteria, most commonly, Streptococcus pneumoniae, Staphylococcus aureus and/or Pseudomonas aeruginosa. The mutations may result in the production of a nonfunctional protein or no protein at all. As a result, the protein cannot relay signals that stimulate an immune response, which allows multiple severe infections to develop.

Waldenström macroglobulinemia is an uncommon lymphoproliferative disorder, characterized by lymphoplasmacytic cells in the bone marrow and overproduction of monoclonal IgM. A characteristic mutation, MYD88 (L625P) found in more than 90 percent of people who develop Waldenström macroglobulinemia. The altered MyD88 protein stimulates the signaling molecules that activate nuclear factor-kappa-B, even without signals from outside the cell. The abnormally active nuclear factor-kappa-B allows survival of abnormal cells that should undergo apoptosis, resulting in the accumulation of lymphoplasmacytic cells in this disorder.

Somatic mutations in MYD88 also contribute to other B cell malignancies such as diffuse large B-cell lymphoma (DLBCL) and marginal zone lymphoma. Mutation of MYD88 gene are present in 50-80% of cases of IgM monoclonal gammopathy of undetermined significance (IgM-MGUS). The individuals with this condition have elevated levels of monoclonal IgM in their serum. IgM-MGUS can transform into Waldenström macroglobulinemia or other B-cell disorder.

  • Confirmation of clinical diagnosis of Waldenström macroglobulinemia
  • Aid in the diagnosis of MYD88 deficiency syndrome
  • As an aid in diagnosis of diffuse large B-cell lymphoma (DLBCL) and marginal zone lymphoma
  • To distinguish lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia (low-grade B-cell lymphoma) from other subtypes
  • Carrier screening in families at risk
The MYD88 L265P abnormality is highly associated (>90%) with the pathologic diagnosis of lymphoplasmacytic lymphoma and the clinical syndrome of Waldenstrom macroglobulinemia (LPL/WM), particularly in the setting of an elevated IgM serum monoclonal paraprotein. Therefore, a positive molecular result supports the possibility of LPL/WM.

Negative for mutations analyzed (No pathogenic variant or mutation detected)

Sequence analysis by bidirectional sequence analysis gene-targeted deletion/duplication analysis by quantitative multiplex PCR, long-range PCR, multiplex ligation dependent probe amplification (MLPA).

Whole Blood (EDTA), bone Marrow, formalin fix paraffin embed tissue (FFPE Tumor Tissue).

Stability

  • Ambient: 3-5 days (blood)
  • Refrigerated: 5 days (whole blood or bone marrow)
  • Ambient: Indefinitely (FFPE)
Serum or urine protein electrophoresis, immunohistochemistry, H/E stain, complete blood count (CBC), IgM level, cryoglobulins, Beta-2 microglobulin (β2M) level, Bone marrow aspiration and biopsy, Fine needle aspiration (FNA) biopsy, Excisional or incisional biopsy, Flow cytometry, CT-guided needle biopsy, CT scan (PET/CT scan).
1-2 weeks.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
  • J Allergy Clin Immunol. 2018;141:1943-1947. [PMID: 29427642]
  • Blood. 2013;121: 2522-8. [PMID: 23355535]
  • J Biol Chem. 2013;288: 12054-66. [PMID: 23460645]
  • N Engl J Med. 2012;367: 826-33. [PMID: 22931316]
  • Genetics Home Reference. Available at: https://ghr.nlm.nih.gov/gene/MYD88#
  • Signal transduction (third edition), in: chapter 13; activation of the innate immune system: The Toll-like receptor -4 and signaling through ubiquitinylation, 2016: 741-775.